NCT00095810
Completed
Phase 4
An Open-Label Study of Aripiprazole to Evaluate the Safety and Tolerability in Patients With Psychosis Associated With Parkinson's Disease
Otsuka Pharmaceutical Development & Commercialization, Inc.1 site in 1 country50 target enrollmentJuly 2003
Overview
- Phase
- Phase 4
- Intervention
- aripiprazole
- Conditions
- Parkinson's Disease
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- Tolerability
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
The purpose of this clinical research study is to assess the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Primary diagnosis of idiopathic Parkinson's disease.
- •Psychosis related to Parkinson's disease.
Exclusion Criteria
- •Psychosis present prior to diagnosis of Parkinson's disease.
Arms & Interventions
A
Intervention: aripiprazole
Outcomes
Primary Outcomes
Tolerability
Secondary Outcomes
- Safety Assessments
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
An Open-Label Trial of Aripiprazole in Autism Spectrum DisordersAutismAsperger's DisorderPervasive Developmental DisorderNCT00308074Cambridge Health Alliance14
Completed
Phase 3
A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric PracticesSchizophreniaNCT00237939Otsuka Pharmaceutical Development & Commercialization, Inc.1,200
Completed
Phase 3
A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric PracticesSchizophrenia and Schizoaffective DisorderNCT00292409Otsuka Pharmaceutical Development & Commercialization, Inc.400
Completed
Phase 3
A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With SchizophreniaSchizophreniaNCT01942148Otsuka Pharmaceutical Co., Ltd.68
Completed
Phase 3
Oral Aripiprazole Open-Label Rollover StudySchizophreniaNCT01001702Otsuka Pharmaceutical Development & Commercialization, Inc.85